Page 1 2 3 4 5 6 Entries 51-75 of 140
August 11, 2016
Researchers are Working on Breath Analysis for Diagnosing Lung Cancer
MedPage Today and the American Society of Clinical Oncology (ASCO) have collaborated on an article describing the potential development of an exhaled breath analysis tool for screening, diagnosis, and monitoring of lung cancer. While the authors admit that the technology is in its infancy, they are using a variety of techniques to test for the presence of several volatile organic compounds in exhaled breath that reveal whether lung cancer is present and whether therapy is working for patients experiencing advanced disease. Initial tests show that such tests on relatively small cohorts of patients are currently 85% as accurate as the current gold standard imaging (Response Evaluation Criteria in Solid Tumors, known as RECIST) that's used for similar purposes today. Eventually, as this technology and a corresponding "electronic nose" evolve, it's hoped that the validity of such technology will be proven for diagnosing and monitoring lung cancer and perhaps even some other cancers as well.
Such out-of-the-box ideas depend on the imagination of talented researchers, a sustained funding stream, the availability of target populations for testing, and of course time. Hopefully all four will be available to advance these ideas toward reality.
July 14, 2016
Cancer Center Advertising: Not Always in the Patient's Best Interest
An interesting article came out from Indiana University on July 11 (and published in the Journal of the American Medical Association JAMA Internal Medicine) calling attention to the increasing volume of advertising that cancer centers are placing on TV and internet media. Since 2005, the volume of such ads has tripled, reflecting increased competition in many of the nation's urban markets. In fact, the authors calculate that 20 out of 890 cancer centers are responsible for 86% of the ads. Some of these are for very credible institutions, like M.D. Anderson Cancer Center and Dana-Farber Cancer Institute, but others are not. In fact, study coauthor Laura B. Vater of Indiana University School of Medicine in Indianapolis says that "Among the 20 centers with the highest spending in 2014, more than half were not designated by the National Cancer Institute, and three were not accredited by the Commission on Cancer. The public should be aware that cancer centers spending the most on advertising may not necessarily provide the highest quality of cancer care."
Many of the ads are designed to appeal to the emotional needs of people facing advanced cancer diagnoses and looking for hope. They rarely address the costs, benefits, and risks of treatment, and they may often build false hopes. If you're looking for a reputable cancer center and are considering one you saw advertised, you may want to look at Indiana University's study. The National Cancer Institute and Commission on Cancer (a program of the American College of Surgeons, ACoS) represent far more reliable resources.
July 5, 2016
CRISPR: Gene Editing is Coming of Age
In my own formal reviews of cancer research grant proposals, I’ve heard reference to CRISPR. Time Magazine’s July 4 cover story sets forth a simple and compelling description of it that explains its power in changing the course of cancer and many other life-threatening diseases. Often diseases stem from the fundamental biology of our genetic code. Each time cells divide inside your body, there is the possibility of a mutation or error occurring. The normal body has a mechanism for correcting or eliminating harmful errors, but sometimes that mechanism doesn’t work. That’s where CRISPR comes in.
Very simply, it fits into the trend toward personalized medicine. Once scientists learn what section of a patient’s DNA has a mutation or flaw that is known to cause or allow cancer or another disease to thrive, CRISPR can be programmed to seek it out and make repairs. It uses an enzyme called Cas9 to find and snip out the bad DNA segment. Then some people’s bodies will repair the DNA on their own, or scientists can insert a corrected strip of DNA.
This technique is influencing biological research, fueling new discoveries of how to turn cancer from an equal opportunity killer to a chronic disease. It’s controversial because it could be used to modify human embryos, so its use is carefully controlled.
What’s important is for people who care about cancer and cancer research to know that these kinds of developments are emerging from medical research that costs a lot and takes enormous time but offers significant hope for controlling conditions like cancer that stem from genomic errors.
June 22, 2016
Call your Senator! 21st Century Cures Bill Needs a Push
When the 21st Century Cures Bill was introduced in Congress last year, it sounded encouraging, even breathtaking for those of us who are eager to see increases in Federal investments in research to support cancer and other life-threatening diseases. It's all about modernizing the government's approach to reviewing and approving medical devices and new pharmaceutical products and increasing research funding by a significant amount.
If a Senate bill doesn't pass by mid-July, when Congress goes on its summer recess, it is unlikely to get attention in the Fall, as the election approaches. That means that 2.5 years of work on both sides of the aisle, in both houses of Congress, will have to begin anew in January. None of us can afford the delay. Both parties need to bend to come up with a bill that will pass the Senate and then be reconciled with the bill that the House passed last summer.
Your senator's contact information is accessible at http://www.senate.gov/senators/contact/. Just click on "state" and the site will resort the list. Let's not let this opportunity go by without letting the grass roots be counted. Please let your senator know you want action quickly.
June 16, 2016
Multiple Myeloma Patients Face Risk of Second Primary Cancers
Multiple myeloma (MM) is a blood cancer that for some patients can be managed into a chronic disease situation. For example: James, who was originally diagnosed over 23 years ago and has had three bone marrow transplants, is now able--with the support of his activist wife and caregiver--to control his MM like a chronic rather than life-threatening condition.
At the recent annual meeting of ASCO (American Society of Clinical Oncology), a research study was released that has strong scientific support of both good and bad news for MM patients.
The good news is that patients diagnosed with MM are living longer, largely because of dramatic treatment advances. The bad news is that studies of large numbers of patients in both Germany and Sweden have shown a steady rise in the incidence of second primary cancers. The most common such cancer was treatment-related leukemia, for which the risk of developing acute myeloid leukemia (AML), kidney cancer, and nervous system cancers is two- to five-fold higher than that of the general population. Some researchers believe that these second primary cancers may in some way be triggered by original MM treatments.
While research works to understand underlying causes and to improve monitoring of MM patients for such second primary cancers, careful monitoring just makes good sense.
May 16, 2016
Potential Progress in Treating Glioblastoma: Bravo!
So often, I hear complaints about cancer research about how long it takes, how much it costs, and why can't it come along faster to save more lives. So when potential breakthroughs develop on the cancer treatment front, they deserve all of our attention and support.
60 Minutes last night featured 40 minutes worth of information about use of altered polio virus to treat glioblastoma, a cancer diagnosis that has, so far, represented a rapid death sentence. The early findings of this Phase I trial, which is intended only to determine safe dosage, led to the FDA granting it Breakthrough status so it can be made available to other patients nationwide.
To catch up with what's happening, go to http://www.cbsnews.com/…/60-minutes-fda-breakthrough-statu…/. It's guaranteed to stimulate hope. Not without bumps along the way, but some miraculous progress, and the FDA wanting to accelerate its availability. Bravo!
May 3, 2016
"Cancer Moonshot" Update: The Space Analogy Works
An interesting article appeared in the WBUR public radio newsletter Cognoscenti on April 29 that helps in explaining why the idea of the "moonshot" was a useful analogy for Joe Biden's cancer initiative, and why we're not wasting our time in hoping for cancer research breakthroughs to emerge.
For those of us old enough to remember the early days of the space program, there were lots of false starts. It took years to develop predictable technologies that could be leveraged successfully from one kind of activity to another. For space research, it was sending a man to the moon, the space station, and so many more developments that demonstrated success. The article's author Fred Ledley, M.D., contends that the space program's eventual success depended on the maturing of technologies (building blocks) that would allow breakthroughs to happen.
Dr. Ledley, who directs the Bentley College Center for Integration of Science and Industry (Waltham, MA) contends that cancer research may well be following a similar model:
Our research suggests that cancer research may now be at a similar stage. Analytical models suggest that many of the discoveries and technologies that are essential components of cancer therapies have now matured to the point that they may predictably generate successful products. In fact, over the past several decades, there have been significantly more new therapies approved, and scientists are optimistic about applying the insights of molecular biology and genomics to achieve cures.
Cancer science may, in fact, be like rocket science emerging from an era of frequent failure. A “moonshot” for cancer could actually work.
To succeed, however, we must recognize that the success of America’s lunar program was built on a foundation of maturing technologies and investments that hastened their development, not new scientific discoveries that would take decades to mature. With increased investment and strategic management, we have a shot at a cure for cancer. This time it will be different.
As someone who is actively engaged in reviewing cancer research grant proposals for the American Cancer Society at both regional and national levels, and as a passionate advocate for increased Federal and private cancer research funding, I hope that Dr. Ledley is right. It's not enough for the cancer survival rate to sneak slowly upward; we need breakthroughs that will address the most lethal cancers, prevent metastasis, and change the trajectory of the disease. It's only through intensive funding to leverage our new learnings about the fundamental mechanisms that trigger cancer cell growth, the process of metastasis, and ways of triggering the human immune system to fight these foreign invaders that we'll be able to accelerate the number of breakthroughs we'll see in our lifetimes.
May 3, 2016
Relapse . . . after 27 Years?
We want to believe it's over, once we've gone through cancer treatments. One and done is what we all want, especially as time passes.
For those of us who are lucky, when treatment for our tiny or non-invasive run-of-the-mill breast cancer is over, we go back for our regular annual check-ups, with cancer fading more and more into our memories. For most of us, our minds save our sanity by pushing our treatment experiences farther back in our consciousness. For those who had more difficult treatment experiences (mastectomies, chemotherapy, prolonged radiation, and so on) with more advanced or challenging types of cancer, it takes longer, if it happens at all.
But there's nothing like the shock of being told it's back--not just that you have cancer again, but that after many many years, the same cancer that was treated by surgery and chemo so long ago, is back. For L, who had had a single mastectomy and chemo 27 years ago, it was stunning to learn that her recently removed appendix was lined with lobular breast cancer cells. She's now having a full body PET scan to see if it has spread farther, and she's meeting with experts at leading cancer institutions to find the right oncologist to take on her case.
To make it even harder, her original hospital no longer has the records (27 years ago was before records were digitized and before patients were routinely given copies of their paper records). Fortunately, after she relocated to this area 17 years ago, the oncologist she saw for her annual checkups (but has since moved out of the area) did have a record that her cancer had been invasive and lobular. Fortunately, too, the records were left behind when he changed institutions, and she found a compassionate medical records clerk who helped her get copies of those records, saying "If it was me, I'd want someone like me to help find them."
So now L has been again dropped into cancer Hell. Her full-body PET scan will help define what treatments will be most appropriate. Her consults with three oncologists at two leading cancer centers will help her select which oncologist to trust with her life. And her family--still somewhat in shock--are clustered around her, taking detailed notes at medical appointments and doing lots of the research that she will need to choose the best oncologist and course of treatment.
I share this story with my readers for its lessons:
- Always get copies of your medical records, even though they're digitized now. Get everything you can get your hands on. It's your body, and they're your records. That includes imaging scans, on CDs, so you can pass them along if you ever need them or just fill a file cabinet if you don't. Make sure you know where your pathology slides will be kept, and for how long. L has been working to get her records and is having good luck, but it's meant a lot of stress and running around.
- Keep doing your routine annual cancer check-ups, like L did, and follow her example: when something is clearly wrong in another part of your body, don't hesitate to pursue a diagnosis with your PCP. An initial CT scan told them she needed surgery.
- When told there might be something going on in her appendix, L and her PCP made a good decision. They had the choice of having a general surgeon remove the appendix or going with a colorectal cancer surgeon, in case he saw something else of concern in the neighborhood. Wise choice.
- Don't assume that it's good news if there's no tumor in the tissue sample that's sent to pathology after a new follow-up or exploratory surgery. Her cancer was in the lining of the appendix, and was not a tumor. Some cancers don't create tumors and so are inoperable. Fortunately the appendix could come out intact, but only the PET scan will tell if it's gone elsewhere beyond the appendix. The problem is that some metastases are mucinous (like fluid). Others, like metastatic lobular breast cancer, may be more like strings or spider webs. For those, chemo may be required because you just can't get it all out through surgery.
Above all, advocate for yourself. Take a deep breath. In spite of your emotional state, you must take a minute to think. Whom do I know who can help? What do I need to do to pin down my options? Chart out a course of action. Once you have things to do and appointments on the calendar, you'll start regaining your sense of control over the situation and your hope for the future.
Finally, don't hesitate to mobilize anyone you know who can pull a string on your behalf to get you an earlier appointment with the right specialists, and don't hesitate to let your friends and family help. Now's the time to temper your past inclinations to care for others. It's time to let others in who want to help care for you.
Twenty seven years. It just takes your breath away, and it reminds us all what an insidious disease we're fighting.
April 7, 2016
Cancer Fund-Raising: Beware of These Scams!
Yes, it's sad but true that there are unscrupulous people out there who would capitalize on cancer patients' suffering as a vehicle to raise money that goes to fill the perpetrators' pockets and not to serve the causes of cancer research or patient care. This article from CNN highlights four of them, together with the scope of their deceipt and the way they did it. Do give to cancer research and patient / caregiver support charities, for sure, but make certain that you steer clear of these bad apples. If you have any doubts about the legitimacy of a particular organization, you can look them up on Guidestar or Charity Navigator to make sure they're among the good guys.
March 28, 2016
How Could Congress Foot-Drag on Cancer Clusters?
"Disease cluster" is the term used to describe communities that experience unexpected increases in the incidence of birth defects, cancer, and other diseases that may be attributable to a common cause. This has been proven to be the case in many communities nationwide where environmental or toxic waste in air or water has been demonstrated to cause disease among people who live in close proximity and within a common time period.
The Centers for Disease Control (CDC) updated its guidelines for investigating cancer clusters in 2013, with particular focus on the techniques to be used in investigating such clusters and for communicating about them with the public. Their intent was to provide public health agencies with the needed decision support tools to promote appropriate and effective local action that would be transparent and built public trust.
In 2011, Sen. Barbara Boxer from California introduced a bill called the Strengthening Protections for Children and Communities from Disease Clusters Act. The bill was intended to help communities to investigate and mount solutions to suspected disease clusters. Despite support from a number of nonprofits, that bill went nowhere, despite its intention to protect our citizens from the impacts of air and water contamination on their health.
A similar bill was re-introduced in 2013, with co-sponsorship of Senator Mike Crapo of Idaho. It went into The Environment and Public Health Committee, where Sen. Boxer is the ranking member. It went nowhere.
A bill was re-introduced on March 12, 2015 as S. 725, the Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act. It is now in committee, where it has sat for a full year, despite having five co-sponsors from varying states. It is being treated as a bill to amend the Toxic Substances Control Act.
Clusters of cancer and other diseases aren't going away. In fact, a map of existing cancer clusters, provided by Erin Brockovitch, should raise widespread concern nationwide:
It is only by pressing our legislators to act on this bill that we will be able to protect ourselves, our family members, and our friends from potentially fatal diseases that could be prevented if we would just stand up to the poisons in our environment. Isn't it time to begin holding our legislators accountable for things that matter, like whether our children are being poisoned?
March 18, 2016
Medical Marijuana May Be Coming of Age
MedPage Today, an electronic medical newsletter, this week cited an article from an investment newsletter (called Seeking Alpha) about pharmaceutical companies' clinical trials for cannabanoid products. Applications for such products include some orphan diseases (currently lacking proven treatments) as well as a range of conditions including cancer, epilepsy, and schizophrenia. Cancer-related products in the pipelines of a variety of companies include treatment for cancer pain, Recurrent Glioblastoma Multiforme, ovarian and pancreatic cancers, and chemotherapy-induced vomiting. The evolution of such products has been marked by a variety of ups and downs, but the general pattern is forward and promising for future approvals, especially for pain control products (like Sativex) that are currently in Phase 3 clinical trials.
March 2, 2016
Research Finding: Potential Mesothelioma Treatment Targets
For those who are suffering from Mesothelioma, one of the cancers with few treatment options, a new development offers future hope. The email newsletter MedPage Today revealed on February 29 that the International Mesothelioma Program at Brigham and Women's Hospital in Boston, working with researchers from Genentech, has discovered some previously unknown genetic mutations in mesothelioma tumors that may offer potential treatments, some of them in the short term.
Mesothelioma is a rare cancer with a 5-10% survival rate. The primary question for patients isn't "How can I be cured?," but rather "How long do I have?" The researchers analyzed 216 malignant pleural mesothelioma (MPM) tumor samples to look for common genetic mutations that might be targeted by existing drugs. The most striking of the findings was that the genetic signature of the mutations most resemble those in ovarian cancer--another problem disease.
Photo from Photobucket. Click here for others.
The research team's hope is that this finding will help in both the diagnostic and treatment processes. The technical aspects of the study may be hard for non-scientists to understand, but the potential seems to be real for those patients who get their tumors genetically sequenced in search of actionable mutations.
February 24, 2016
Creating Meaning from the Unthinkable
The words "cancer" and "kids" represent a horrifying combination for many of us. My Huffington Post piece released yesterday picks up on that issue through the story of Oliver Strong and his family. They are seeking meaning by seeking out the causes of pediatric cancers, which appear to be concentrated in a cluster in the Miami area. If I say so myself, the story is compelling, and the actions his family is taking are uplifting. They illustrate how cancer caregivers try to create meaning as they heal. Take a read, and please refer others to this article:
January 29, 2016
Cancer Researchers Find a "First" Cancer Cell
Cancer's origins in the body remain a mystery to researchers. Yet researchers at Boston Children's Hospital (Dr. Leonard Zon and Dr. Charles K. Kaufman and their colleagues) published in the journal Science their discovery of a single cell in a normal and healthy zebra fish that turned cancerous. Their results were described in the New York Times on January 29 in an article "A Single Cell Shines New Light on How Cancers Develop," by Gina Kolata.
Zebra fish are often used by cancer researchers because they are transparent and reproduce quickly. The transparency allows researchers to see what's happening "real time" inside the fish without cutting it open.
The Zon Laboratory discovered a gene in a zebra fish embryo that creates the fish skin and includes the ability to turn cancerous. When the fish is born, that gene is turned off and the cells grow normally. However, occasionally the gene turns on again and produces a tumor in an adult fish. By fusing the gene to a fluorescent substance that would light up when the gene went on inside a cell, the scientists were able to demonstrate that every time the light went on, the fish developed melanoma. The team's hypothesis is that the cell returned to an embryonic state, where it became cancerous and then overrode the normal off switch so it could grow and spread the cancer through the body of the fish.
This is a fascinating idea that offers promise for learning how melanoma and other cells become cancerous. Researchers from other institutions are calling this a significant advance in the field.
Kolata's story is easy reading for research laymen, but fascinating for anyone interested in learning more about the kinds of developments that research funding is making possible. These kinds of discoveries are expensive and take considerable time, but they offer clues about ways of controlling melanoma and other cancers in the future.
January 14, 2016
Finally, a "Moonshot" Against Cancer!
When President Obama announced the cancer moonshot initiative at the State of the Union speech, thousands of cancer patients, survivors, and caregivers cheered and cried at the same time. Then the New York Times on January 14 gave us a dose of sobriety in Gina Kolata's and Gardiner Harris' article entitled "'Moonshot' to Cure Cancer, to Be Led by Biden, Relies on Outmoded View of Disease."
The idea of an intense government assault on cancer isn't new. In fact, the first "war on cancer" happened nearly 50 years ago and didn't achieve its goal. Yet it is true that the right kind of leadership from within the government can produce meaningful impacts on the disease. There's no doubt that for Joe Biden, it's personal. Late in 2015, the Vice President helped negotiate a $264 million increase in funding for the National Cancer Institute, what Kolata and Harris termed "the largest in a decade for an agency that has been squeezed by static budgets in recent years."
Further, the variety of developments that have come to fruition in the past decade is helping us to understand the vast diversity of diseases that the word "cancer" represents and therefore the complexity of trying to "cure cancer." Our new insights about the complexity of curing cancer have driven a variety of research developments and emerging therapies that are targeted toward specific genetic mutations and activating the body's immune system to attack cancer. Such work is highlighting opportunities to find genetic mutations that exist in multiple kinds of cancers and suggests the potential for applying therapies proven for one type of cancer to treating cancers of other types.
Data sharing will also be an important part of the moonshot initiative, so that researchers can build on each others' ideas. Stand Up 2 Cancer, an organization launched within the entertainment industry, has already demonstrated how fast-track initiatives based on collaboration among teams from different research labs can bring new developments to market faster.
By increasing cancer research funding, driving more collaboration within the field, instituting more cancer-friendly Medicare payment guidelines, and streamlining FDA approval requirements, this moonshot initiative may be able to do what the earlier "war on cancer" couldn't: create a world in which cancer is managed as a chronic (rather than so-often fatal) disease and in which the treatments don't torture the patients they're intended to help.
In the end, all we can do as individuals is keep contributing to cancer research, voting for candidates who support intensified cancer research, and hoping that this latest initiative will fulfill our wildest hopes and dreams for controlling this equal-opportunity killer. My New Year's wish is for every current and future cancer patient live to enjoy the label "NED," which stands for "no evidence of disease."
January 5, 2016
Expedited FDA Drug Approvals Bring Hope to Cancer Patients
The Food and Drug Administration has just announced that "In 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel new therapies – significantly more than the average of 28 we have approved during the previous nine years of this decade." Novel new drugs, as defined by the FDA, are innovations that serve needs that were previously unserved or otherwise help advance patient care and public health.
The announcement states that 60% of the new drugs were treated with expedited review as Fast Track (31%), Breakthroughs (22%), Priority Review (53%), and/or Accelerated Approval (13%). In fact, 87% of these approvals were processed on their first approval cycle, without requests for additional information that would have delayed approval. 64% received approval in the United States before getting approval in any other country. The FDA says that it focuses not only on quantity of drugs approved, but also on their quality. In other words, there is no indication that expedited approval has in any way jeopardized patient safety.
While not all of these drugs are applicable to cancer, the 2015 wave of approvals reflects progress in getting bureaucracy out of the way of healing. Many of these new drugs represent new molecular structures while others represent novel biologics; some are first in class. New cancer treatments have been approved for advanced metastatic breast cancer, pediatric high-risk neuroblastoma (brain tumors), multiple myeloma, non-small cell lung cancer, metastatic melanoma, metastatic colorectal cancer, and soft tissue carcinoma.
It is striking that the rate of filings for such expedited approvals has not increased at the same rate. Filings for New Molecular Entities and Biologic License Applications only average 35 per year over the past year. That suggests a great need for all of us to accelerate funding of cancer research that will bring more such dramatic progress. Every reader of this blog can help, either by contributing to private cancer research or by pressing Congress to keep increasing cancer research funding.
We can make this happen, if each of us affected by cancer just cares enough to take action.
December 30, 2015
Immunotherapy Cited by Oncologists as a "Game-Changer"
MedPage Today, an oncology/hematology newsletter, cited on December 27 the results of a survey of 50 oncologists and hematologists about what they see as the important game-changing pharmaceutical advances of 2015. Of the respondents, 74% cited immunotherapy drugs as the most important developments that are coming to the fore in their efforts to control cancer in their patients.
A number of these treatments are extending survival time without increasing toxicity to the patient, and others which have been successful for one kind of cancer are proving transferrable to other types. The respondents cited pecific targeted therapies and FDA approval of numerous "checkpoint inhibitors" which can be turned on or off to cause the immune system to attack the cancer. Sometimes cancer "inhibits" the ability of the immune system to attack the invading cells, and turning off that reaction can help the body to fight the disease.
These developments are exciting and potentially life-saving. Stay tuned, and "watch this space"!
December 14, 2015
E-Cigarettes Found to Contain Hidden Toxins
STAT, a new online health news service, on December 8 (2015) released a story revealing that 80% of the brands of flavored e-cigarettes--which are designed to appeal to people seeking to break the smoking habit and particularly to appeal to children and young adults--contain numerous toxic chemicals, the worst of which is Diacetyl. This chemical causes a condition called "popcorn lung," which is irreversible and potentially requires a lung transplant if the smoker is to survive. It is particularly powerful when heated. Potential buyers who ight see titles like Cupcake, Fruit Squirts, and Oatmeal Cookie can be tricked into thinking this is a safe and entertaining substitute for cigarettes.
If you or a loved one is using e-cigarettes today, you might want to check out the source article at http://www.statnews.com/2015/12/08/e-cigarette-flavorings-dangerous-chemicals/.
December 9, 2015
FDA Approves Device to Reduce Chemo-Induced Hair Loss
One of the more challenging side effects of many chemotherapy treatments for many cancer patients, regardless of age or gender, is hair loss. The negative psychological impact of hair loss can be significant and cause both depression and erosion of self-concept, thereby adding to the stress of cancer treatment.
In March of this year, I shared some promising developments to help reduce hair loss. The idea of cooling the chemo-patient's scalp so the blood there will absorb less of the toxic chemi ias been explored since the mid-1990s. Now a new form of the "cool cap" to help reduce chemo-triggered hair loss was just approved by the Food and Drug Administration. For readers who are seeking additional information, I'm repeating below my blog post of March 11, 2015 in the hopes that it will help some of my readers:
* * *
It's not just women who lament losing their hair when faced with chemotherapy treatments, most of which are hostile to hair. Even four-year-old Eric was upset to have to shave his head in advance of his aggressive treatment for a rare lymphoma.
Well, the New York Times (Tara Parker-Pope) wrote on March 9, 2015 of a new treatment that applies a cold cap to the scalp before, during, and for two hours after a chemotherapy infusion. Apparently the concept has been in practice for over 20 years, but new and improved technology has just gone through its first clinical trial and isn't yet available in most hospitals. It's a good sign of a new development that offers both the opportunity for those in treatments to boost their self-esteem during chemo and increased privacy for those who don't want to walk around virtually advertising, through their baldness, that they're in cancer treatment.
For more information about the concept, history, and alternative types of caps that are being introduced to medical centers for rental, you may want to visit The Rapunzel Project. This site also offers information about Cold Caps Assistance Projects, which helps patients to cover around half of the $600 per month rental expense, depending on need. For access to the supporting research, information about how to get a "starter kit," tips for hair care during chemotherapy using the caps, and a list of the hospitals currently either offering cold cap therapies or with the needed freezer equipment to do so, see the CCAPS site.
Also, you may want to see The Cancer Knowledge Network's blog (April 17, 2015) on this topic.
November 24, 2015
Lives Changed within 36 Hours
We all think it couldn't happen to our family, losing a child to cancer. That's what Vilma Tarzana and Simon Strong thought. Until it happened.
Vilma is a news anchor with Univision in Miami, Simon is president of an information services company, and Oliver was their first-born son. 12-years old. Handsome and healthy. Doing well in school, a leader in his class, and an elite soccer goalie for his team. Happy. Loved his younger brother, and was leading an almost charmed life.
Then one day he got a headache that wouldn't go away. The pediatrician diagnosed it as an infection and prescribed antibiotics. Then, when it didn't clear, the diagnosis became "must be a virus." In desperation, his parents took Oliver to the emergency room at Miami Children's Hospital where tests disclosed a diagnosis that even three pediatric oncologists couldn't agree on: acute myeloid Leukemia (AML), an aggressive blood and bone marrow cancer with a 50% survival rate for children.
Faster than could have been imagined, Oliver's breathing became labored, and his last words before being intubated were "Mommy, Mommy, I'm going to die!" The cancer virtually exploded inside his lungs and his heart stopped. The team of 25 medical professionals in the critical care unit couldn't revive him. Just 36 hours after arriving at the hospital, Oliver was declared dead.
In their efforts to understand how this could have happened, Vilma and Simon are trying to learn why childhood cancers are increasing in prevalence and what causes them. This information is proving difficult to obtain, although they have discovered a cancer "cluster" near their home in Florida. They are also exploring why children who play goalie on artificial turf are being more affected than other children.
The family has created a foundation http://oliverforeverstrong.com/, in an effort to explain the lack of insight into pediatric cancers and to raise money that can fuel more research into causes so other families can avoid such tragedies in the future. They are receiving invaluable publicity for the effort through Univision.
I hope you'll share this link with others who have children. We need to stop these kinds of tragedies.
November 20, 2015
Dogs Represent A Potential New Cancer Detection Tool
CNN announced today that Lucy, a combination Labrador retriever and Irish water spaniel, has been trained to sniff out bladder, kidney, and prostate cancers. Despite having failed at guide dog school, her owners noted that her curiosity and attention to random scents might offer potential for other training applications, like smelling out cancer. Lucy is now part of a clinical trial and has demonstrated 95% accuracy in her "diagnoses.")
Medical Detection Dogs has eight dogs in Britain who can identify from urine samples what National Health Services patients have such cancers as melanoma, breast cancer, and ovarian cancer. Other organizations have proven dogs' ability to sniff out when a diabetic patient is lapsing into hypogycemia (dangerously low blood sugar).
This phenomenon has been noted since 1989 and results from the fact that dogs have s60 times as many sensors in their noses and a second smelling system that humans lack. The combination is capable of picking up on volatile organic compounds that are excreted by many cancers.
The potential of this discovery is enormous, and it should give us all a new appreciation for an animal long known as "man's best friend."
November 5, 2015
Dancing through Stage 4 Cancer, Spreading Hope
October 23, 2015
Animal Studies Reveal Clues about Human Cancers
Recent news about genetic discoveries in animals (none of which damaged the animals but rather involved blood draws and so on) have revealed some exciting prospects for discoveries about the genetic, biological, and immunological mechanisms that contribute to cancer's prevalence in people. I released an article today in Huffington Post on the topic. You can read it there by clicking on the link in the prior sentence, or keep reading below:
Animal Studies Offer Cancer Research Clues
Posted: 10/22/2015 7:43 pm EDT Updated: 10/22/2015 7:59 pm EDT
What do an elephant, a blind mole rat, and bowhead whales have in common that could help people? There are indications that all of them have different sorts of cancer resistance built into their DNA and body processes. The National Cancer Institute (NCI) describes such animal models as central to understanding how cancer works in the human body.
According to the American Cancer Society, roughly one of two men and one of three women will be diagnosed with cancer in their lifetimes. Over three quarters of those diagnoses come in people above the age of 55, but cancer can strike at any age.
Animals get cancer too, but many do so at radically lower rates than people. In the 1970s, epidemiologist Richard Peto of University of Oxford, UK, studied larger and especially long-lived animals, whose cells have divided many more times than those of smaller and younger animals. His opening hypothesis was that these larger and older animals should have more random mutations that could lead to cancer. Surprisingly, he discovered that they actually contracted cancer far less frequently, so he suspected that they might have some built-in biological mechanism that was protecting them from the disease.
More recently, the labs of Dr. J. D. Schiffman (from the Huntsman Cancer Center at the University of Utah) and Dr. Vincent Lynch (evolutionary biologist at the University of Chicago) have each independently identified a significant factor that may help explain the difference in cancer incidence rates between people and elephants. A gene common to people and elephants called TP53 helps suppress cancer. The p53 protein helps identify when a gene has been damaged and may stimulate repair of the gene, pause cell division, or cause the cell to kill itself.
Humans have two copies of this tumor suppressor gene and have a lifetime cancer risk ranging from 33 - 50% (one in two men, one in three women). In contrast, elephants have 20 or more copies of this tumor suppressor gene, and their lifetime cancer risk is dramatically lower: under 5%. It remains to be experimentally proven whether TP53 is responsible for this cross-species difference in cancer risk. Yet in rare human cases where a human TP53 gene is defective (a rare disorder called Li-Fraumeni syndrome), the person's lifetime cancer risk may rise as high as 90%.
Many research labs are examining cancer trends in a variety of animal species that have particularly low cancer incidence for possibly different reasons. Researchers don't fully understand (yet) the mechanisms responsible for reduced cancer incidence in certain species but are now exploring more species for potential human parallels. Particular targets of investigation in animals include two gene types [one that causes normal cells to turn cancerous (oncogenes) and one that suppresses cancer by repairing cell damage and stopping tumor growth] as well as a variety of proteins and enzymes.
For example, the naked mole rat, a subterranean rodent that lives over 30 years (in comparison with the typical four-year life span of more typical rats), is resistant to both cancer and aging. Researchers believe this phenomenon is a function of an enzyme, hyaluronidase (HA). Because cancer is more prevalent in older humans, learnings from long-lived animals with low cancer rates could be relevant. Other long-lived species like parrots, tortoises, and bowhead whales are subjects of Dr. Schiffman's interest, although their cancer suppression mechanisms (as-yet unknown) may be different from either TP53 or the HA enzyme.
Discoveries of how these genes and enzymes behave in animal models may decipher the biological mechanisms that cause, support, prevent, or suppress cancers in the human body. Researchers seek to discover mechanisms in animal models that may help control human cancer's incidence, growth, spread, and potential to kill.
The exploration of such models is only one facet in cancer research but offers an important lesson about why cancer research costs so much and takes so long. Cancer isn't just one disease. It's the name for over 200 related conditions in which unrestrained cell growth may overwhelm the body's normal organs and systems. Controlling cancer requires understanding for each type of cancer such factors as its causes, mechanisms that allow or even foster its spread (metastasis), how some cancers develop chemotherapy resistance, and what causes recurrences after a patient goes into remission.
The American Association for Cancer Research (AACR) describes four basic levels of research that are pivotal to breakthroughs for humans:
- Basic laboratory research studies normal cells and what transforms them into cancer cells.
- Translational research works to convert laboratory discoveries into potentially safe and effective patient treatments.
- Clinical research conducts trials with people to determine safe and effective dosages, on what types of patients, with what types and stages of cancers. Some trials also test whether effective treatments for one type of cancer may work for other types as well.
- Population research examines volumes of clinical data to understand risk, incidence, and survival patterns across large population groups to reveal prevention, detection, or control breakthroughs.
Animal models represent only one link in the cancer research chain. Cancer research is further complicated by the overlay of genetic patterns that make each person more or less susceptible to cancer and by biological "switches" that may trigger the body's own immune system to fight cancer. The resulting breadth of potential research targets makes cancer research both costly and time consuming.
While it's unclear what human applications such research might have, Dr. Ted Gansler of the American Cancer Society says that
"Studies of other species that are done . . . without any short term expectation of medical relevance often turn out to be very important in understanding cancer . . . . progress often comes from unexpected directions."
Despite rising survival rates, current human cancer incidence (one new case diagnosed every 30 seconds) poses an extreme financial and emotional toll for affected families. Animal studies are time consuming and costly but will continue to yield important clues about cancer in humans, clues that will be missed or delayed without substantially increased Federal research funding.
September 21, 2015
Children's Cancer Awareness? Empathy is Far From Enough
Earlier this month, I received a blog post from the Cancer Knowledge Network, a very good information source that's published by people who have lost children to cancer. Sue McKechnie released a post about her son Shawn, who died of brain cancer at age 3. It's compelling reading, and I've picked up on her story in an article that I posted today on Huffington Post. If I say so myself, it's compelling and well worth a look: http://www.huffingtonpost.com/deborah-j-cornwall/childhood-cancer-empathy-_b_8158070.html
Hopefully it will inspire some readers to speak out in support of more funding for pediatric cancer research.
September 10, 2015
Finally, Legislation Addressing the High Price of Prescription Drugs
The Wall Street Journal just released a story about a bill that Bernie Standers and Elijah Cummings are introducing to the Senate and House today the Prescription Drug Affordability Act at a press conference today (September 10). It's goals are to allow citizens to import less costly drugs from Canada, empower Medicare to negotiate drug prices with pharmaceutical manufacturers, and require manufacturers to disclose the prices at which they sell their products overseas.
Pay attention to this bill as more details are disclosed and as our legislators begin to take sides. On the surface, this bill would appear to have positive impact for a large share of the American population. Regardless of your political preferences, it's clear that as the bill proceeds through Congressional consideration in both houses, there will be opportunities for impassioned advocates to communicate their feelings about it to legislators.
Page 1 2 3 4 5 6 Entries 51-75 of 140